卡托普利联合美托洛尔治疗慢性心功能衰竭60例临床分析被引量：19

导出

摘要目的探讨卡托普利、美托洛尔联合应用治疗慢性心力衰竭的临床疗效。方法将119例中老年慢性心力衰竭患者分为对照组和联合治疗组,联合治疗组在常规治疗基础上加用卡托普利、美托洛尔,治疗6个月后评价心功能,治疗前及治疗用心脏彩超测定左心室舒张末期内径及收缩末期内径、室间隔厚度及左心室射血分数。结果联合治疗组心功能改善总有效率明显高于对照组,两组比较差异有统计学意义(P<0.05),联合治疗6个月后左心室舒张末期内径及收缩末期内径减小,室问隔厚度变薄,左心室射血分数提高,与对照组比较差异有统计学意义(P<0.05)。结论卡托普利、美托洛尔联合应用能抑制或逆转心脏重塑,改善患者心功能及生活质量,降低病死率,改善预后。

作者明志红肖伟黄雁玲

机构地区肇庆市第一人民医院北岭分院

出处《中国现代医生》 2010年第3期47-48,共2页 China Modern Doctor

关键词卡托普利美托洛尔心力衰竭心脏重塑

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献3

1慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量：2410
2胡大一,吴彦.规范心力衰竭治疗加强患者管理[J].中华心血管病杂志,2005,33(6):495-497. 被引量：124
3吴学思.中国慢性心力衰竭指南2007版要点[J].中华内科杂志,2008,47(4):267-268. 被引量：30

二级参考文献11

1Stewart S, Maclntyre K, Macleod MM, et al. Trends in hospitalization for heart failure in Scotland, 1990-1996. An epidemic that has reached its peak? Eur Heart J,2001, 22:209-217.
2Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J,2001,22:1527-1560.
3Felker GM, Adams KF Jr, Konstam MA, et al. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J,2003,145:S18-S25.
4Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail,2001,3:283-291.
5Coletta AP, Cleland JG, Freemantle N, et al. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Fail,2003,5:697-704.
6Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators.Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med, 2005, 352:225-237.
7Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med, 2005,352:1539-1549.
8Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet,2004 ,364:141-148.
9Arnold JM, Yusuf S, Young J, et al. HOPE Investigators. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation,2003,107:1284-1290.
10Fox KM. European trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet,2003,362:782-788.